Ilsung Pharmaceuticals Co., Ltd. (003120.KS)
KRW 15970.0
(-0.19%)
KRW 15970.0
(-0.19%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 78.05 Billion | 61.24 Billion | 42.08 Billion | 40.6 Billion | 48.41 Billion | 61.65 Billion |
| Cost of Revenue | 43.33 Billion | 33.31 Billion | 25.95 Billion | 27.41 Billion | 30.24 Billion | 39.05 Billion |
| Gross Profit | 34.71 Billion | 27.93 Billion | 16.13 Billion | 13.18 Billion | 18.16 Billion | 22.59 Billion |
| Operating Expenses | 42.47 Billion | 26.63 Billion | 17.93 Billion | 15.12 Billion | 19.42 Billion | 20.33 Billion |
| Selling, General and Administrative Expenses | 40.94 Billion | 14.78 Billion | 9.14 Billion | 5.98 Billion | 9.23 Billion | 9.96 Billion |
| Research and Development Expenses | 1.52 Billion | 1.51 Billion | 99.08 Million | 109.21 Million | 93.48 Million | 131.81 Million |
| Other Expenses | - | 10.34 Billion | 8.68 Billion | 9.03 Billion | 10.09 Billion | -343.24 Million |
| Cost and Expenses | 85.8 Billion | 59.95 Billion | 43.88 Billion | 42.54 Billion | 49.66 Billion | 59.39 Billion |
| Operating Income | -7.75 Billion | 140.22 Billion | 1.62 Billion | -298.55 Million | 226.76 Million | 2.25 Billion |
| Interest Expense | 23.87 Million | 12.63 Million | 12.63 Million | 13.88 Million | 5.44 Million | 10 Thousand |
| Income Tax Expense | -404.04 Million | 32.73 Billion | -155.82 Million | 1.19 Billion | 2.46 Billion | 1.64 Billion |
| Earnings before Tax | -21.34 Billion | 137.97 Billion | -1.52 Billion | 4.41 Billion | 9.17 Billion | 4.58 Billion |
| Net Income | -20.94 Billion | 108.66 Billion | -1.36 Billion | 3.22 Billion | 6.71 Billion | 2.94 Billion |
| Earnings Per Share Basic | -2994.34 | 2906.49 | -178.32 | 419.91 | 971.73 | 438.40 |
| Earnings Per Share Diluted | -2994.34 | 2906.49 | -178.32 | 419.91 | 971.73 | 438.40 |
| Weighted Average Shares Outstanding | 6.99 Million | 37.38 Million | 7.66 Million | 7.66 Million | 6.91 Million | 6.71 Million |
| Weighted Average Shares Outstanding (Diluted) | 6.99 Million | 37.38 Million | 7.66 Million | 7.66 Million | 6.91 Million | 6.71 Million |
| Gross Margin | 0.44 | 0.46 | 0.38 | 0.32 | 0.38 | 0.37 |
| EBIT Margin | -0.24 | 2.34 | 0.11 | 0.07 | 0.07 | 0.11 |
| Profit Margin | -0.27 | 1.77 | -0.03 | 0.08 | 0.14 | 0.05 |
| EBITDA | -18.47 Billion | 145.29 Billion | 1.56 Billion | 1.11 Billion | 1.82 Billion | 5.27 Billion |
| Earnings Before Tax Margin | -0.10 | 2.29 | 0.04 | -0.01 | 0.00 | 0.04 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 17.14 Billion | 15.98 Billion | 78.05 Billion | 22.02 Billion | 18.07 Billion | 20.02 Billion |
| Cost of Revenue | 11.35 Billion | 10.09 Billion | 43.33 Billion | 13.04 Billion | 10.55 Billion | 9.24 Billion |
| Gross Profit | 5.78 Billion | 5.89 Billion | 34.71 Billion | 8.97 Billion | 7.51 Billion | 10.78 Billion |
| Operating Expenses | 8.79 Billion | 9.19 Billion | 42.47 Billion | 9.78 Billion | -8.98 Billion | -13.4 Billion |
| Selling, General and Administrative Expenses | 8.58 Billion | 8.87 Billion | - | 9.51 Billion | 8.98 Billion | 13.4 Billion |
| Research and Development Expenses | 207.45 Million | 314.07 Million | - | 273.92 Million | 440.3 Million | 69.04 Million |
| Other Expenses | 156.02 Million | -379.87 Million | -138.94 Million | -367.59 Million | -17.97 Billion | -26.8 Billion |
| Cost and Expenses | 20.14 Billion | 19.28 Billion | 85.8 Billion | 22.83 Billion | 10.55 Billion | 9.24 Billion |
| Operating Income | -3 Billion | -3.29 Billion | -7.75 Billion | -816.22 Million | -1.46 Billion | -2.61 Billion |
| Interest Expense | 9.08 Million | 9.21 Million | 23.87 Million | 11.39 Million | 2.91 Million | 6.58 Million |
| Income Tax Expense | -32.1 Million | 40.56 Million | -404.04 Million | -6.14 Billion | 1.35 Billion | -787.06 Million |
| Earnings before Tax | -453.9 Million | -626.08 Million | -21.34 Billion | -45.85 Billion | 5.83 Billion | -2 Billion |
| Net Income | -421.8 Million | -666.64 Million | -20.94 Billion | -39.7 Billion | 4.48 Billion | -1.21 Billion |
| Earnings Per Share Basic | -61.89 | -97.81 | - | -5825.42 | 657.53 | -172.87 |
| Earnings Per Share Diluted | -61.89 | -97.81 | - | -5825.42 | 657.53 | -172.87 |
| Weighted Average Shares Outstanding | 6.81 Million | 6.81 Million | 6.99 Million | 6.81 Million | 6.81 Million | 7.02 Million |
| Weighted Average Shares Outstanding (Diluted) | 6.81 Million | 6.81 Million | 6.99 Million | 6.81 Million | 6.81 Million | 7.02 Million |
| Gross Margin | 0.34 | 0.37 | 0.44 | 0.41 | 0.42 | 0.54 |
| EBIT Margin | -0.13 | -0.16 | - | -0.02 | 0.42 | 0.54 |
| Profit Margin | -0.02 | -0.04 | -0.27 | -1.80 | 0.25 | -0.06 |
| EBITDA | -2.16 Billion | -2.5 Billion | - | -463.94 Million | 7.51 Billion | 10.78 Billion |
| Earnings Before Tax Margin | -0.18 | -0.21 | -0.10 | -0.04 | -0.08 | -0.13 |
1452
1OJ
VEDL
4477
T1L
SPCG-R